China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced that its subsidiary, Evive Biotech Ltd, has received marketing approval from the Brazil National Health Surveillance Agency (ANVISA) for Ryzneuta (efbemalenograstim alfa, F-627). This approval follows previous marketing nods in China, the United States, and the European Union.
Ryzneuta (F-627): A Potential First-in-Class rhG-CSF
F-627, developed through the proprietary Di-Kine bimolecular technology platform, is a potential first-in-class recombinant human granulocyte colony-stimulating factor (rhG-CSF). It is characterized by its long-lasting and potent biological properties. The drug is applied to prevent and treat neutropenia, a condition caused by chemotherapy in cancer patients, where the white blood cell count drops, making them vulnerable to infections.
Enhancing Immune Response and Patient Safety
Ryzneuta can rapidly proliferate and recover neutrophils in cancer chemotherapy patients, thereby enhancing the immune system’s ability to resist infections. This effect is crucial in preventing patients from dying from infections or other related complications during chemotherapy, ultimately improving patient safety and outcomes.-Fineline Info & Tech
